Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13.

Fundamental & Clinical Pharmacology
Xuejian WangWen-Fang Xu

Abstract

Aminopeptidase N (APN) plays an important role in tumor progression, which participates in the progress such as proliferation, attachment, angiogenesis, and tumor invasion. All of this makes APN as a good chemical therapeutic anti-tumor target. In this study, a series of chemically synthesized APN inhibitors were tested for the anti-tumor activities, and three most effective compounds were chosen according to the MTT assay. Then, the enzyme inhibitory, anti-tumor, specificity, angiogenesis, and invasion were determined to evaluate the activity of these three compounds. All compounds can markedly inhibit the enzyme activity of APN, angiogenesis of endothelial cells, and the invasion of ES-2 cells. And it had little effect on the viability of K562 which express low level of APN. This data indicated that the tested compounds were APN hit compounds. We also did kinetic assay to determine the inhibition constant and constructed a three-dimensional quantitative structure-activity relationship model to analyze the structure-activity relationship to direct the further design of novel APN inhibitors as anti-tumor agents. These data demonstrate that the tested compounds can be developed as novel candidates of anticancer agent.

References

Jan 1, 1976·The Journal of Antibiotics·H UmezawaT Takeuchi
Apr 1, 1989·The Journal of Clinical Investigation·A T LookS C Peiper
Oct 31, 1994·FEBS Letters·N M Hooper
Mar 31, 1999·Immunology Today·D RiemannJ Langner
Jun 13, 2000·Advances in Experimental Medicine and Biology·U LendeckelD Reinhold
Jun 13, 2000·Advances in Experimental Medicine and Biology·H SjöströmJ Olsen
May 12, 2001·Pathology Oncology Research : POR·A John, G Tuszynski
Feb 23, 2002·Journal of Molecular Graphics & Modelling·Alexander Golbraikh, Alexander Tropsha
Sep 5, 2003·Chemistry & Biology·Joong Sup ShimHo Jeong Kwon
Sep 19, 2003·Journal of Computer-aided Molecular Design·Alexander GolbraikhAlexander Tropsha
Apr 24, 2004·Science·Marie E EganMichael J Caplan
Jan 13, 2006·Biochemical Pharmacology·Jarkko I VenäläinenPekka T Männistö
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takahiro TokuharaMasayuki Miyake
Mar 17, 2007·Blood·Nenad PetrovicLinda H Shapiro
Mar 31, 2007·Nature Reviews. Drug Discovery·Judah Folkman
Sep 25, 2007·Biochemical and Biophysical Research Communications·Eunju YangHo Jeong Kwon
Feb 27, 2008·Bioorganic & Medicinal Chemistry·Shridhar S KulkarniTanaji T Talele
Mar 21, 2008·Journal of Molecular Modeling·Minyong LiYanqing Zhang
May 10, 2008·Bioorganic & Medicinal Chemistry·Qiang WangWenfang Xu
May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Ute BankMichael Tager

❮ Previous
Next ❯

Methods Mentioned

BETA
FCS
FACS

Software Mentioned

QSAR
ripos S ybyl
O rigin
OriginLab
Sybyl

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.